Meridian Bioscience (VIVO) Reports In-Line Q2 EPS

Meridian Bioscience (NASDAQ: VIVO) reported Q2 EPS of $0.22, in-line with the analyst estimate of $0.22. Revenue for the quarter came in at $48.2 million versus the consensus estimate of $48.6 million.

For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Lockheed Martin frontrunner for $3.5B Ultra Maritime deal, sources say - FT
• Danone SA (BN:FP) (DANOY) PT Raised to EUR63 at Deutsche Bank